glp-1 substance use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and disorders: An emerging pharmacotherapeutic target GLP-1 drugs transform lives of

Description

As off-label use continues to expand, particularly among patients with obesity or insulin resistance, our findings suggest GLP-1based therapies may warrant consideration as an adjunct to insulin in carefully selected patients. Advertisement Advertisement New service for patients with diabetes will make annual screening more convenient Association revises criteria for the diagnosis and resolution of severe conditions What to consider in the management of euglycemic DKA Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals Familiarity will enhance its accessibility for patients with diabetes New study counters earlier findings linking drugs with eye disease Study highlights the value of quantitative ultra-widefield angiography Longevity in healthcare, personal experiences may provide caregivers with false sense of confidence

They have since been embraced for their effectiveness in promoting weight loss

However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects -cell mass or alters the progressive loss of insulin secretory capacity in humans

The first dose was a loading dose of subcutaneous exenatide 20 mcg or equivalent volume of subcutaneous 0.9% saline placebo

[1] Important safety considerations include the risk of hypoglycaemia when combined with insulin or sulfonylureas, potential dehydration and acute kidney injury with severe gastrointestinal symptoms, and for semaglutide specifically, possible worsening of diabetic retinopathy in those with pre-existing disease